Niagen Bioscience
NAGE
64 hedge funds and large institutions have $33.2M invested in Niagen Bioscience in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 16 closing their positions.
113% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 8
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
20% more capital invested
Capital invested by funds: $27.7M → $33.2M (+$5.45M)
10% more funds holding
Funds holding: 58 → 64 (+6)
4.26% more ownership
Funds ownership: 12.04% → 16.3% (+4.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.74M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.92M |
| 3 |
TCM
Tieton Capital Management
Yakima,
Washington
|
+$1.32M |
| 4 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$1.02M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$920K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.12M |
| 2 |
Goldman Sachs
New York
|
-$964K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$772K |
| 4 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$523K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$427K |
NAGE Hedge Fund Activity: Q2 2018 in Review
64 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q2 2018, worth a combined $33.2M — up 20% from $27.7M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NAGE positions and 16 closed out — a net gain of 6 holders — while 17 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $6.74M. The largest seller was Millennium Management, exiting entirely with an estimated $2.12M sold.
- 64 institutional investors held Niagen Bioscience (NAGE) as of Q2 2018, up from 58 in Q1 2018.
- Funds reported $33.2M of Niagen Bioscience stock for Q2 2018, up 20% quarter-over-quarter.
- 22 funds opened new Niagen Bioscience positions in Q2 2018 and 16 closed out, a net change of +6 holders.
- The largest Niagen Bioscience buyer in Q2 2018 was BlackRock, an estimated $6.74M added.
- The largest Niagen Bioscience seller in Q2 2018 was Millennium Management, an estimated $2.12M sold.
Based on aggregated 13F filings for Q2 2018.